INDIA – Alkem Laboratories Limited, an Indian multinational pharmaceutical company headquartered in Mumbai, has forayed into the field of Ophthalmology.
Similarly, Alkem Laboratories Ltd. expanded its product portfolio with the launch of its novel antibiotic that is effective against multidrug-resistant (MDR) bacteria under the brand name Zidavi.
The launch of Alkem’s antibiotic for MDR infections is in line with the company’s endeavor to ensure affordability, accessibility, and availability while saving the lives of critically ill patients.
The Indian pharmaceutical company engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products. It operates through the pharmaceutical business segment.
The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals in acute and chronic therapeutic areas.
Consequently, Alkem Laboratories has ventured into the Ophthalmology space in India with the launch of an extensive portfolio of affordable and quality eye care products.
In a press release, the pharma giant said: “This strategic expansion demonstrates Alkem’s commitment to innovation and its dedication to meeting the diverse needs of patients suffering from various eye conditions.”
The nationwide launch includes a line-up of brands targeting key therapeutic categories for Alkem’s ophthalmology segment.
Alkem’s entry into the ophthalmology segment is anticipated to improve access to high-quality, affordable eye care formulations for patients in India.
By ensuring the accessibility and availability of eye care formulations, the pharmaceutical company hopes to elevate the standard of eye care and improve the overall well-being of patients.
“Alkem introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launch by providing innovative, quality, and affordable solutions to ophthalmologists, who play a pivotal role in managing and treating eye diseases,” the company said in a statement.
Each sales package includes a scannable QR code that provides accessible Interactive multilingual patient education in a user-friendly and inclusive manner through a dedicated patient education website.
It is in line with Alkem’s commitment to advancing healthcare and providing innovative solutions at affordable rates to patients suffering from eye diseases worldwide.
The global ophthalmology market is expected to gain market growth in the forecast period of 2023 to 2030.
Data Bridge Market Research analyses that the market is growing with a CAGR of 6.4% in the forecast period of 2023 to 2030 and is expected to reach US$84,655.95 million by 2030, from US$51,459.32 million in 2022.
Commenting on the new business arrangement, Sandeep Singh, Managing Director of Alkem Laboratories, said: “We are delighted to begin this new chapter in Alkem’s journey by entering the field of Ophthalmology.”
Sandeep Singh pointed out that the strategic move will allow Alkem to introduce new, innovative, and futuristic formulations soon.
“With our comprehensive product range and a patient-centric approach, we aim to empower ophthalmologists to provide exceptional care and improve patients,” underscored Sandeep Singh.
Moreover, the company forays into the Ophthalmology space shortly after Enzene Biosciences Limited, the biological arm of Alkem Laboratories, launched a biosimilar version of Roche’s Avastin in the Indian market.
Enzene Biosciences has begun manufacturing its novel Avastin biosimilar product as a way to bring new therapeutic options for patients with multiple cancer types.
It aligns with the company’s mission to deliver innovative and affordable biomanufacturing for novel biologics and biosimilars globally.
Comparably, Alkem Oncology launched Cetuxa, the first similar biologic of cetuximab used in the treatment of head and neck cancer, in India earlier this year.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
